Crude incidence rates of tuberculosis and nontuberculous mycobacterial disease (NTM) among antitumour necrosis factor (TNF) users, Kaiser Permanente Northern California, 2000–2008
| Crude incidence rate (95% CI)* tuberculosis NTM | ||
|---|---|---|
| 1All Anti-TNF users | 49 (18-79) | 74 (37-111) |
| aEtanercept users | 17 (0-41) | 35 (1-69) |
| bInfliximab users | 83 (10-156) | 116 (30-203) |
| cAdalimumab users | 91 (19-267) | 122 (3-241) |
| dMonoclonal users | 123 (43-222) | 168 (84-301) |
| 2Anti-TNF users, >50 years old | 64 (26-132) | 118 (63-202) |
↵* rate per 100 000 patient years (95% CI).
† All anti-TNF users: 10 tuberculosis cases/20 409 person-years, 15 NTM cases/20 270 person-years.
‡ Etanercept users: 2 tuberculosis cases/11 765 person-years, 4 NTM cases/11 429 person-years.
§ Infliximab users: 5 tuberculosis cases/6024 person-years, 7 NTM cases /6035 person-years.
#Adalimumab users: 3 tuberculosis cases/3285 person-years, 4 NTM cases/3279 person-years.
¶ Infliximab or adalimumab users: 8 tuberculosis cases/6508 person-years, 11 NTM cases/6542 person-years.
** anti-TNF users, ≥50 years old: 7 tuberculosis cases/11 011 person-years, 13 NTM cases/11 017 person-years.